Top Biologics for Eosinophilic Esophagitis

Eosinophilic esophagitis (EoE) is a chronic allergic condition that causes inflammation of the esophagus. It is characterized by a high number of white blood cells called eosinophils in the esophageal tissue. This can lead to symptoms such as difficulty swallowing, chest pain, and food impaction. While there is no cure for EoE, biologic medications have emerged as a promising treatment option for managing the condition. Biologics are a type of medication that target specific molecules in the immune system to reduce inflammation and improve symptoms. Here are some of the top biologics currently being used to treat EoE: 1. Dupilumab: Dupilumab is a monoclonal antibody that targets a protein called interleukin-4 receptor alpha, which plays a key role in the immune response. Studies have shown that dupilumab can significantly reduce eosinophil levels in the esophagus and improve symptoms in patients with EoE. 2. Reslizumab: Reslizumab is a monoclonal antibody that targets interleukin-5, a protein that is involved in the production and activation of eosinophils. Clinical trials have demonstrated that reslizumab can reduce eosinophil levels in the esophagus and improve swallowing difficulties in patients with EoE. 3. Mepolizumab: Mepolizumab is another monoclonal antibody that targets interleukin-5. Studies have shown that mepolizumab can reduce eosinophil levels in the esophagus and improve symptoms in patients with EoE. 4. Benralizumab: Benralizumab is a monoclonal antibody that targets interleukin-5 receptor alpha, which is involved in the activation of eosinophils. Clinical trials have shown that benralizumab can reduce eosinophil levels in the esophagus and improve symptoms in patients with EoE. While biologics have shown promise in the treatment of EoE, it is important to note that they may not be effective for all patients. It is essential to work closely with a healthcare provider to determine the best treatment plan for managing EoE symptoms.